NeuroTrauma Sciences reported data on its novel neuroactive small molecule NTS-105 in a poster presentation at the 39th Annual Symposium of the National Neurotrauma Society in Atlanta, GA.
NeuroTrauma Sciences today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury.
Preclinical research to focus on sleep, inflammation and efficacy of the NTS compound NTS-104 in TBI
The study demonstrated the ability of NTS-105 to reduce cell death at a wide range of concentrations in preclinical models of TBI.
Dr. Parry will discuss recent advances in the development of novel neurosteroids for the treatment of traumatic brain injury.
Comments are closed.